The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial.
about
Olanzapine versus other atypical antipsychotics for schizophreniaAmisulpride versus other atypical antipsychotics for schizophreniaThe effectiveness and safety of amisulpride in Chinese patients with schizophrenia who switch from risperidone or olanzapine: a subgroup analysis of the ESCAPE study.Effects of drop-out on efficacy estimates in five Cochrane reviews of popular antipsychotics for schizophrenia.Methodological issues in current antipsychotic drug trials.World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance.Almost all antipsychotics result in weight gain: a meta-analysis.Efficacy of amisulpride and olanzapine for negative symptoms and cognitive impairments: An open-label clinical studyDo negative symptoms of schizophrenia change over time? A meta-analysis of longitudinal data.Quantifying clinical relevance in the treatment of schizophrenia.Negative symptoms of schizophrenia: a problem that will not go away.Pharmacological treatment of negative symptoms of schizophrenia: therapeutic opportunity or cul-de-sac?Differential diagnoses and management strategies in patients with schizophrenia and bipolar disorderSocial functioning as an outcome measure in schizophrenia studies.Dropout rates in randomized clinical trials of antipsychotics: a meta-analysis comparing first- and second-generation drugs and an examination of the role of trial design featuresComparing tolerability of olanzapine in schizophrenia and affective disorders: a meta-analysis.The SWITCH study: rationale and design of the trial.Update on the management of symptoms in schizophrenia: focus on amisulpride.Amisulpride versus olanzapine in the treatment of schizophrenia in Indian patients: randomized controlled trial.Comparative efficacy and safety between amisulpride and olanzapine in schizophrenia treatment and a cost analysis in China: a systematic review, meta-analysis, and cost-minimization analysis
P2860
Q24236545-6A7C2735-7815-4710-9506-2F624D13334BQ24240433-DD70B338-0519-479E-8C4F-F506CA04CB27Q33609974-16CE7BA5-23C6-451A-A437-97BA79EA16CFQ34266750-BB299F22-C4CE-4652-A73B-DBED12B8822BQ34587745-C4C98EAB-7600-4033-863F-B7B00FA6EA5FQ34640811-5CEB7A10-B40E-4E01-AAB1-27E2DF7E6E9AQ34661499-03EB0A2E-7D46-487A-A57F-F6D3E894A94EQ34665354-254C6E50-6C3B-4AA9-B038-8DE5D2431A34Q35450483-CB23ED5B-7DF6-4A8D-AF4D-A0AF79DA8135Q35819467-F57FCB34-EDC6-4E60-B7A3-AA871110EA88Q36698647-FEF170FA-D181-47EC-B5C7-CC5B42EB1D1EQ36715888-9AB2A9B6-C422-473D-BF1E-E6484D380795Q36836740-D9A647F4-49D6-4C0B-B1D5-1DCAA55D1F00Q36973846-214E47E9-1485-4659-89B6-FEB383B04406Q37227479-55BDA6FE-4490-433F-B246-1EFAF7B2B522Q38042478-56CA3583-1479-4A97-941D-252EDBBB751AQ38979325-B75D1113-D1AE-4BF4-A2BB-6C3BDF0CD0BDQ41529086-02104397-F5E3-4087-B1B0-7A43950F6E9AQ43202107-30E6D6D0-C62B-432B-BA10-80F5851A75B3Q58763260-4BB66442-005A-46F1-89A2-E0675D4E5300
P2860
The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
The treatment of negative symp ...... ind controlled clinical trial.
@en
The treatment of negative symp ...... ind controlled clinical trial.
@nl
type
label
The treatment of negative symp ...... ind controlled clinical trial.
@en
The treatment of negative symp ...... ind controlled clinical trial.
@nl
prefLabel
The treatment of negative symp ...... ind controlled clinical trial.
@en
The treatment of negative symp ...... ind controlled clinical trial.
@nl
P2093
P2860
P1476
The treatment of negative symp ...... ind controlled clinical trial.
@en
P2093
M Bouhassira
S Lancrenon
Y Lecrubier
P2860
P304
P356
10.1111/J.1600-0447.2006.00887.X
P407
P577
2006-11-01T00:00:00Z